| 0 (0%) | 09-27 11:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.61  |
1-year : | 10.13 |
| Resists | First : | 8.22 |
Second : | 8.68 |
| Pivot price | 7.85 |
|||
| Supports | First : | 7.5 |
Second : | 6.24 |
| MAs | MA(5) : | 7.75 |
MA(20) : | 7.96 |
| MA(100) : | 9.09 |
MA(250) : | 8.32  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 12.8 |
D(3) : | 17.9 |
| RSI | RSI(14): 36.7 |
|||
| 52-week | High : | 11.31 | Low : | 6.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BCRX ] has closed above bottom band by 16.7%. Bollinger Bands are 50.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.74 - 7.8 | 7.8 - 7.84 |
| Low: | 7.36 - 7.43 | 7.43 - 7.49 |
| Close: | 7.53 - 7.63 | 7.63 - 7.7 |
Wed, 24 Sep 2025
37,800 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Purchased by Strs Ohio - MarketBeat
Tue, 23 Sep 2025
Voya Investment Management LLC Sells 129,093 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Fri, 05 Sep 2025
BioCryst Pharmaceuticals Stock (BCRX) Opinions on Q2 Revenue Surge and Conference Insights - Quiver Quantitative
Tue, 02 Sep 2025
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 Revenue Soars 49%, Hits Record $163.4 Million on ORLADEYO Surge - MSN
Thu, 21 Aug 2025
What BioCryst Pharmaceuticals (BCRX)'s Leadership Change and $90M Shelf Offering Mean for Shareholders - simplywall.st
Thu, 21 Aug 2025
Biotech Developer BioCryst Pharmaceuticals to Present Latest Updates at Major Cantor Healthcare Conference - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 210 (M) |
| Shares Float | 208 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 95.8 (%) |
| Shares Short | 27,480 (K) |
| Shares Short P.Month | 25,880 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.01 |
| Profit Margin | -6.5 % |
| Operating Margin | 18.2 % |
| Return on Assets (ttm) | 7.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 49.4 % |
| Gross Profit (p.s.) | 1.76 |
| Sales Per Share | 2.65 |
| EBITDA (p.s.) | 0.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 17 (M) |
| Levered Free Cash Flow | 54 (M) |
| PE Ratio | -42.39 |
| PEG Ratio | 0 |
| Price to Book value | -3.8 |
| Price to Sales | 2.87 |
| Price to Cash Flow | 95.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|